Knapp

Stefan Knapp

Affiliations

Goethe University

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

All Publications

2024

Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε.

Haag A, Němec V, Janovská P, Bartošíková J, Adhikari B, Müller J, Schwalm MP, Čada Š, Ohmayer U, Daub H, Kim Y, Born F, Wolf E, Bryja V, Knapp S

J Med Chem. 2024-12-27 . .doi: 10.1021/acs.jmedchem.4c02201

PMID: 39729064

Probing the Protein Kinases' Cysteinome by Covalent Fragments.

Wang G, Seidler NJ, Röhm S, Pan Y, Liang XJ, Haarer L, Berger BT, Sivashanmugam SA, Wydra VR, Forster M, Laufer SA, Chaikuad A, Gehringer M, Knapp S

Angew Chem Int Ed Engl. 2024-12-24 . e202419736 .doi: 10.1002/anie.202419736

PMID: 39716901

DARPins as a novel tool to detect and degrade p73.

Münick P, Zielinski J, Strubel A, Gutfreund N, Dreier B, Schaefer JV, Schäfer B, Gebel J, Osterburg C, Chaikuad A, Knapp S, Plückthun A, Dötsch V

Cell Death Dis. 2024-12-19 . 15(12):909 .doi: 10.1038/s41419-024-07304-2

PMID: 39695090

Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example.

Sander P, Schwalm MP, Krämer A, Elson L, Rasch A, Masberg B, Selig R, Sievers-Engler A, Lämmerhofer M, Müller S, Knapp S, Albrecht W, Laufer SA

J Med Chem. 2024-12-17 . .doi: 10.1021/acs.jmedchem.4c02552

PMID: 39681301

Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets.

Schwalm MP, Dopfer J, Kumar A, Greco FA, Bauer N, Löhr F, Heering J, Cano-Franco S, Lechner S, Hanke T, Jaser I, Morasch V, Lenz C, Fearon D, Marples PG, Tomlinson CWE, Brunello L, Saxena K, Adams NBP, von Delft F, Müller S, Stolz A, Proschak E, Kuster B, Knapp S, Rogov VV

Nat Commun. 2024-11-26 . 15(1):10204 .doi: 10.1038/s41467-024-54409-5

PMID: 39587067

The endocannabinoid anandamide mediates anti-inflammatory effects through activation of NR4A nuclear receptors.

Teichmann T, Pflüger-Müller B, Giménez VMM, Sailer F, Dirks H, Zehr S, Warwick T, Brettner F, Munoz-Tello P, Zimmer A, Tegeder I, Thomas D, Gurke R, Günther S, Heering J, Proschak E, Geisslinger G, Bibli IS, Heringdorf DMZ, Manucha W, Windbergs M, Knapp S, Weigert A, Leisegang MS, Kojetin D, Brandes RP

Br J Pharmacol. 2024-11-20 . .doi: 10.1111/bph.17366

PMID: 39563075